Cargando…

A risk‐based approach to identifying oligometastatic disease on imaging

Recognition of <3 metastases in <2 organs, particularly in cancers with a known predisposition to oligometastatic disease (OMD) (colorectal, prostate, renal, sarcoma and lung), offers the opportunity to focally treat the lesions identified and confers a survival advantage. The reliability with...

Descripción completa

Detalles Bibliográficos
Autores principales: deSouza, Nandita M, Tempany, Clare M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492106/
https://www.ncbi.nlm.nih.gov/pubmed/30098215
http://dx.doi.org/10.1002/ijc.31793
_version_ 1783415082532732928
author deSouza, Nandita M
Tempany, Clare M
author_facet deSouza, Nandita M
Tempany, Clare M
author_sort deSouza, Nandita M
collection PubMed
description Recognition of <3 metastases in <2 organs, particularly in cancers with a known predisposition to oligometastatic disease (OMD) (colorectal, prostate, renal, sarcoma and lung), offers the opportunity to focally treat the lesions identified and confers a survival advantage. The reliability with which OMD is identified depends on the sensitivity of the imaging technique used for detection and may be predicted from phenotypic and genetic factors of the primary tumour, which determine metastatic risk. Whole‐body or organ‐specific imaging to identify oligometastases requires optimization to achieve maximal sensitivity. Metastatic lesions at multiple locations may require a variety of imaging modalities for best visualisation because the optimal image contrast is determined by tumour biology. Newer imaging techniques used for this purpose require validation. Additionally, rationalisation of imaging strategies is needed, particularly with regard to timing of imaging and follow‐up studies. This article reviews the current evidence for the use of imaging for recognising OMD and proposes a risk‐based roadmap for identifying patients with true OMD, or at risk of metastatic disease likely to be OM.
format Online
Article
Text
id pubmed-6492106
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-64921062019-05-01 A risk‐based approach to identifying oligometastatic disease on imaging deSouza, Nandita M Tempany, Clare M Int J Cancer Mini Review Recognition of <3 metastases in <2 organs, particularly in cancers with a known predisposition to oligometastatic disease (OMD) (colorectal, prostate, renal, sarcoma and lung), offers the opportunity to focally treat the lesions identified and confers a survival advantage. The reliability with which OMD is identified depends on the sensitivity of the imaging technique used for detection and may be predicted from phenotypic and genetic factors of the primary tumour, which determine metastatic risk. Whole‐body or organ‐specific imaging to identify oligometastases requires optimization to achieve maximal sensitivity. Metastatic lesions at multiple locations may require a variety of imaging modalities for best visualisation because the optimal image contrast is determined by tumour biology. Newer imaging techniques used for this purpose require validation. Additionally, rationalisation of imaging strategies is needed, particularly with regard to timing of imaging and follow‐up studies. This article reviews the current evidence for the use of imaging for recognising OMD and proposes a risk‐based roadmap for identifying patients with true OMD, or at risk of metastatic disease likely to be OM. John Wiley & Sons, Inc. 2018-10-09 2019-02-01 /pmc/articles/PMC6492106/ /pubmed/30098215 http://dx.doi.org/10.1002/ijc.31793 Text en © 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Mini Review
deSouza, Nandita M
Tempany, Clare M
A risk‐based approach to identifying oligometastatic disease on imaging
title A risk‐based approach to identifying oligometastatic disease on imaging
title_full A risk‐based approach to identifying oligometastatic disease on imaging
title_fullStr A risk‐based approach to identifying oligometastatic disease on imaging
title_full_unstemmed A risk‐based approach to identifying oligometastatic disease on imaging
title_short A risk‐based approach to identifying oligometastatic disease on imaging
title_sort risk‐based approach to identifying oligometastatic disease on imaging
topic Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492106/
https://www.ncbi.nlm.nih.gov/pubmed/30098215
http://dx.doi.org/10.1002/ijc.31793
work_keys_str_mv AT desouzananditam ariskbasedapproachtoidentifyingoligometastaticdiseaseonimaging
AT tempanyclarem ariskbasedapproachtoidentifyingoligometastaticdiseaseonimaging
AT desouzananditam riskbasedapproachtoidentifyingoligometastaticdiseaseonimaging
AT tempanyclarem riskbasedapproachtoidentifyingoligometastaticdiseaseonimaging